Weekly Shot Melts Pounds, Knees Go Quiet

Syringe and stethoscope on arthritis document
Photo: Shutterstock

A weekly injection just helped obese adults with knee osteoarthritis cut their pain nearly in half, according to a new phase 3 trial published in the New England Journal of Medicine.

Quick Take

  • Two large phase 3 trials tested retatrutide, an experimental weekly injection, in adults with knee osteoarthritis and obesity.
  • Patients on the highest doses saw WOMAC pain scores drop by roughly 3.7 to 4.0 points over 68 to 80 weeks, versus about 2.1 to 1.9 points with placebo.
  • About two-thirds of treated patients had at least a 50% pain reduction, compared to 38% on placebo.
  • Drugmaker Eli Lilly developed retatrutide, and it has not yet won approval for knee osteoarthritis specifically.

What The New Trial Data Actually Showed

Researchers ran two separate phase 3 trials, called TRIUMPH-4 and TRIUMPH-1-OA, testing retatrutide against a placebo in adults carrying extra weight and dealing with knee osteoarthritis pain. The results appeared in the New England Journal of Medicine on November 8, 2026. In TRIUMPH-4, patients on 9 milligram doses saw their WOMAC pain scores fall by 3.96 points after 68 weeks. Patients on 12 milligrams dropped 3.74 points. Placebo patients improved by 2.12 points.

The second trial, TRIUMPH-1-OA, told a similar story over a longer 80-week stretch. Patients on 4, 9, and 12 milligram doses saw pain drops of 3.22, 3.48, and 3.64 points. Placebo patients improved by 1.87 points. The pattern held across both trials: higher doses tracked with bigger pain relief, and every dose beat placebo by a wide enough margin that researchers ruled out chance as the explanation.

Why The Weight Loss Numbers Matter Just As Much

Retatrutide did not just ease pain. Patients on the highest dose lost close to 25% of their body weight, a scale of weight loss that rivals bariatric surgery for some patients. Eli Lilly’s own data, released around the same time at the ACR Convergence 2026 medical conference, described pain drops of up to 4.5 WOMAC points, a 75.8% reduction from a starting score of 6.0.

Roughly two-thirds of people taking retatrutide reported at least a 50% cut in knee pain. Only 38% of placebo patients hit that same mark. For anyone who has watched a parent or spouse struggle to climb stairs because of bad knees, that gap is the kind of number that changes daily life, not just a lab report.

Reading The Fine Print Behind The Headline

Here is the part worth slowing down for. The placebo group also got better, improving by roughly 2 points on its own. That is a well-documented pattern in pain trials, driven by things like extra attention from doctors and natural symptom swings. So the actual added benefit from retatrutide, beyond what a placebo already delivers, was about 1.6 to 1.8 points, not the full 3.7 to 4.0 point drop. Both figures are real. They just answer different questions.

The trial also measured pain and body weight, not whether the drug repairs cartilage or slows joint damage. No MRI scans of joint tissue or X-ray measurements of joint-space narrowing have been reported yet. That means the honest claim is that retatrutide eases osteoarthritis symptoms, not that it reverses or cures the underlying disease.

It is also impossible yet to say how much of the pain relief came from the drug itself versus simply carrying less body weight. Losing a quarter of your body weight takes pressure off every joint below the belt, regardless of what triggered the loss. Separating those two effects will take more detailed analysis of the trial data than has been made public so far.

What Comes Next For Patients And Regulators

Retatrutide remains an investigational drug. Eli Lilly funded and ran these trials and released much of the early data at its own investor and conference events, a standard practice but one that still means the company has a direct financial stake in how the results are framed. The drug does not yet carry regulatory approval for treating knee osteoarthritis, so doctors cannot prescribe it for that specific purpose today.

For the roughly one in five American adults living with osteoarthritis, a drug that tackles both excess weight and joint pain in one weekly shot would be a meaningful option, if it clears the remaining regulatory and scientific hurdles. The published numbers are genuinely encouraging. They are also a reminder that a headline percentage and a placebo-adjusted result can tell two different, equally true stories about the same drug.

Patients watching this space should expect more data releases as Lilly pursues approval, including longer-term follow-up on whether the pain relief holds up after people stop the injections or regain weight.

Sources:

sciencedaily.com, nejm.org, europepmc.org